Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.
The FDA Shake-Up Continues, And Could Impact Genetic Medicines Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND
